LDN 193688 is a BMP kinase inhibitor preferential for the ALK2 site, acting by binding to the ALK site, with BMP inhibitory activity 100 times that of TGFbetaRI, used in the study of progressive osseous fibrodysplasia.
Molecular Weight:
352.39
Purity:
99.16%
CAS Number:
[1062368-51-7]
Formula:
C22H16N4O
Target:
ALK|||TGF-beta/Smad
T205964
* VAT and and shipping costs not included. Errors and price changes excepted